Researchers at Ohio University have discovered what may be a new way to fight lung cancer that is resistant to other treatments. The study, published in the International Journal of Molecular Science ...

Daiichi Sankyo announced that the first patient has been dosed in the global phase 3 TROPION-Lung17 trial. The study is evaluating DATROWAY in patients with locally advanced or metastatic nonsquamous ...

A new study by researchers at Wake Forest University School of Medicine has identified a promising strategy to treat brain ...

Modelling indicates that over a 20-year period, a national screening programme could detect around 9,000 lung cancers and potentially save more than 6,000 lives – an estimated 300 lives each year.

As a nonsmoker lung cancer hasn't been a concern of mine, but I recently heard it can affect people who have never smoked. If ...

The trials in breast, lung, and colorectal cancer, supported by ARPA-H, will focus on guiding decisions across different lines of therapy using serial biopsies and tumor profiling.

The approval was based on a cohort of treatment-naïve patients in the Beamion LUNG-1 trial who had unresectable or metastatic, non-squamous NSCLC with HER2 tyrosine kinase domain mutations.

Hernexeos is the second drug to secure an FDA approval under the agency’s priority voucher scheme, following in the footsteps of USAntibiotics’ Augmentin XR, which was granted the ticket in December ...

Suchan still needed chemotherapy and radiation, but Salgia credits Rybrevant for shrinking her tumors 60 to 70%. It specifically targets her cancer cells and revs up the immune system. For a year and ...

Malaysia has a new national plan to tackle cancer, tuberculosis, and chronic respiratory conditions in a single approach. Jacqui Thornton reports.

Hernexeos underwent an ultra-rapid 44-day regulatory review due to its inclusion in the FDA Commissioner's National Priority Voucher pilot program.

Boehringer Ingelheim received approval from the Food and Drug Administration for Hernexeos as a treatment for lung cancer. The newly approved indication was granted under accelerated approval based on ...